MAST THERAPEUTICS, INC.
Vepoloxamer, a proprietary amphipathic copolymer therapeutic for acute ischemic stroke
- Sector
- Biotech
- Total capital
- $250K
- Federal grants
- $250K
- 1 award · 2016
- Rank in peer group#217 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 16 pending · first 2016
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · To determine the effect of a combination treatment with vepoloxamer and tissue plasminogen activator on infarct volume and functional outcome in a rat model of embolic stroke$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#70 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- R. Martin EmanueleResearcherExecutive OfficerLinked by $250K in grants as PI
- Brandi L. RobertsExecutive OfficerNamed in SEC Form D filings
- Brian M. CulleyExecutive Officer, DirectorNamed in SEC Form D filings
- David A. RamsayDirectorNamed in SEC Form D filings
- Gregory D. GorgasExecutive OfficerNamed in SEC Form D filings
- Jack M. LiefDirectorNamed in SEC Form D filings
Show all 9 people
- Lewis A. ShusterDirectorNamed in SEC Form D filings
- Patrick L. KeranExecutive OfficerNamed in SEC Form D filings
- Santosh J. VetticadenExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 17- PendingReduced Sodium POLOXAMER-188 Formulations And Methods For UseUSPTOApplication 15742858
- PendingDiuretic Induced Alterations Of Plasma VolumeUSPTOApplication 15029614
- GrantedPoloxamer Composition Free Of Long Circulating Material And Methods For Production And Uses ThereofUSPTOUS 9,403,941
Show all 17 patent records
- Reduced Sodium POLOXAMER-188 Formulations And Methods For UseMar 14, 2019 · Application 15742858Pending
- Diuretic Induced Alterations Of Plasma VolumeAug 18, 2016 · Application 15029614Pending
- Poloxamer Composition Free Of Long Circulating Material And Methods For Production And Uses ThereofAug 2, 2016 · US 9,403,941Granted
- Methods And Compositions For Improving HemostasisJan 7, 2016 · Application 14793730Pending
- Methods For Enhancing Oxygenation Of Jeopardized TissueApr 2, 2015 · Application 14553913Pending
- Methods For Enhancing Oxygenation Of Jeopardized TissueJul 11, 2013 · Application 13783158Pending
- Methods And Compositions For Improving HemostasisApplication PCTUS2015039456Pending
- Diuretic Induced Alterations Of Plasma VolumeApplication PCTUS2014060982Pending
- Poloxamer Therapy For Heart FailureApplication PCTUS2014045627Pending
- Treatment Of Diuretic Induced Alterations Of Plasma VolumeApplication 61891856Pending
- Poloxamer Therapy For Heart FailureApplication 62126400Pending
- Methods For Enhancing Oxygenation Of Jeopardized TissueApplication PCTUS2011060747Pending
- Polyoxyethylene/polyoxypropylene Copolymers And Fibrinolytic Inhibitors, Uses Thereof And CompositionsApplication PCTUS2016041304Pending
- Reduced Sodium POLOXAMER-188 Formulations And Methods For UseApplication PCTUS2016041374Pending
- Poloxamer Therapy For Heart FailureApplication PCTUS2015039426Pending
- Polyoxyethylene/polyoxypropylene Copolymers And Fibrinolytic Inhibitors, Uses Thereof And CompositionsApplication 62189705Pending
- A Poloxamer Composition Free Of Long Circulating Material And Methods For Production And Uses ThereofApplication PCTUS2015039418Pending
Related companies, and why
- REVIVA PHARMACEUTICALS HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- KYRON, INC.Similar federal contract value in Biotech · null in contracts
- MBQ PHARMA INC.Similar federal contract value in Biotech · null in contracts
- NEUROPATHIX, INC.Similar federal contract value in Biotech · null in contracts
- CHESAPEAKE GENOMIC SYSTEMS, LLCSimilar federal contract value in Biotech · null in contracts
- Biohaven Environmental Solutions, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .